Skip to main content

Advertisement

Table 2 Diagnostic performance of preoperative CE-MRI in different molecular tumor subtypes

From: Radiologic complete response (rCR) in contrast-enhanced magnetic resonance imaging (CE-MRI) after neoadjuvant chemotherapy for early breast cancer predicts recurrence-free survival but not pathologic complete response (pCR)

Percentage (95% CI) All Luminal A Luminal B HER2+/HR+ HER2+/HR- TNBC P value*
pCR rate 29% 5% 28% 30% 49% 37%
Sensitivity 75% (63–84%) 33% (1–91%) 100% (56–100%) 73% (39–94%) 63% (35–85%) 79% (61–91%) 0.120
Specificity 67% (59–74%) 74% (60–85%) 57% (32–76%) 54% (33–73%) 53% (28–77%) 74% (60–84%) 0.139
PPV 48% (38–57%) 7% (0.2–32) 47% (22–69%) 40% (19–64%) 56% (31–78%) 63% (47–78%) 0.003
NPV 87% (79–92%) 95% (84–99%) 100% (68–100%) 82% (57–96%) 60% (32–84%) 86% (73–94%) 0.009
Accuracy 69% (63–75%) 72% (58–83%) 69% (49–84%) 59% (42–75%) 58% (39–74%) 76% (65–84%) < 0.001
  1. CE-MRI contrast-enhanced magnetic resonance imaging, pCR pathologic complete response, PPV positive predictive value, NPV negative predictive value, HER2 human epidermal growth factor receptor 2, TNBC triple-negative breast cancer
  2. *Fisher’s exact test for all subgroups